Stefan Grathwohl

Title: Innovations by Stefan Grathwohl in Neurological Treatments

Introduction

Stefan Grathwohl is an accomplished inventor based in Unterengstringen, Switzerland. He has made significant contributions to the field of neuroscience, particularly in the treatment of microglia-mediated disorders. His innovative work has the potential to impact the lives of many individuals suffering from neurological and neurodegenerative diseases.

Latest Patents

Stefan Grathwohl holds 1 patent for his invention titled "Compounds and methods for use in the treatment of microglia-mediated disorders." This patent describes M1 muscarinic acetylcholine receptor (mAChR) agonists that are used to promote the viability and activation of microglia and macrophages. The invention aims to enhance the survival and activation of these cells by increasing levels of sTREM2 released by microglia cells. Additionally, the patent outlines pharmaceutical compositions and methods for preparing these compounds, which are suitable for treating or preventing conditions that require microglia and macrophage modulation.

Career Highlights

Stefan Grathwohl is associated with Nsc Therapeutics GmbH, where he continues to advance his research and development efforts. His work focuses on innovative solutions for neurological disorders, showcasing his commitment to improving patient outcomes through scientific discovery.

Collaborations

Stefan collaborates with notable colleagues in the field, including Abraham Fisher and Roger Nitsch. These partnerships enhance the research and development process, fostering an environment of innovation and shared expertise.

Conclusion

Stefan Grathwohl's contributions to the field of neuroscience through his patent and collaborative efforts highlight his dedication to advancing treatments for neurological disorders. His work exemplifies the impact of innovation in improving health outcomes for individuals affected by these conditions.